| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product sales, net | 4,952 | 4,825 | 845 | 4,496 |
| Cost of goods sold | 905 | 755 | 365 | 869 |
| Research and development | - | - | - | 332 |
| Amortization of intangible asset | - | 107 | - | - |
| Gain on change in accounting estimates on contingent royalty liability (note 7) | 1,933 | - | - | - |
| Amortization of intangible asset | 80 | 100 | 223 | 301 |
| Research and development, net | 470 | 746 | -5,035 | - |
| Selling and marketing | 2,391 | 2,625 | 2,600 | 2,382 |
| General and administrative | 2,088 | 1,843 | 2,365 | 3,052 |
| Total operating expenses | 4,001 | 6,076 | 518 | 6,936 |
| Income (loss) from operations | 951 | -1,251 | 327 | -2,440 |
| Interest income | 3 | 2 | 8 | 3 |
| Gain on debt extinguishment, net | - | 0 | - | -143 |
| Loss on issuance of financial instruments | - | 0 | - | - |
| Other expense, net | 682 | 662 | 600 | 562 |
| Change in fair value of financial instruments | -1,845 | 134 | 1,221 | 769 |
| Total other income (expense), net | -2,524 | -526 | 629 | 67 |
| Loss before income tax benefit (expense) | -1,573 | -1,777 | 956 | -2,373 |
| Income tax benefit (expense) | -4 | 7 | - | -8 |
| Net loss | -1,569 | -1,784 | 956 | -2,365 |
| Convertible and redeemable preferred stock deemed dividends | 111 | -1 | -3 | -5 |
| Net loss attributable to common stockholders | -1,680 | -1,785 | 953 | -2,370 |
| Net loss per share attributable to common stockholders- basic | -0.01 | -0.02 | 0.01 | -0.02 |
| Net loss per share attributable to common stockholders- diluted | -0.01 | -0.02 | 0 | -0.02 |
| Weighted-average shares used to compute net loss per share attributable to common shareholders - basic | 119,578,093 | 115,686,024 | 113,356,354 | 96,459,121 |
| Weighted-average shares used to compute net loss per share attributable to common shareholders - diluted | 119,578,093 | 115,686,024 | 6,039,898,041 | 96,459,121 |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)